

25th March 2025

Dear Valued Customer,

Re: Update on Australian supply of Pegasys® (peginterferon alfa-2a)

Echo Therapeutics Pty Ltd is the registered sponsor of Pegasys® (peginterferon alfa-2a) [AUST R 91836 and 91879]. Firstly, we thank you for your assistance and understanding with the transition to the Pegasys® Home Delivery Program via our partner [JustMeds](#). We also wanted to provide an update on the current status with available local supply of Pegasys® for Australian patients.

As you are aware, we have undertaken significant measures to extend available supply, such as the Pegasys® Home Delivery Program, amidst the supply shortage that many other countries have been facing. Presently, we are down to just under three months supply, with no definitive timeline of when replenishment stock of Australian labelled Pegasys® will become available. This anticipated shortage is listed on the [TGA Medicines Shortages website](#). While we are hopeful that there will be no significant supply interruption, we are mitigating with options such as supplying foreign-labelled stock under section 19A of the TGA *Therapeutic Goods Act 1989* to ensure patients can continue to access treatment.

In the unlikely event of a protracted shortage, we seek your assistance with treatment management strategies for newly initiated and existing patients. Overseas, there have been examples of alternative dosing being considered, or even delaying starting new patients on Pegasys®. Whilst Echo Therapeutics is exploring all supply options, we request your support to help manage patients' disease and expectations during this time. Additional information and guidance is available at the [HSANZ website](#) including a [video link](#) where Dr Cecily Forsyth discusses possible strategies to consider in your practice.

We believe that with urgent support from yourself and/or via a consultative group of physicians of the HSANZ, these treatment management strategies will help ensure any disruption to patient care (whether new or existing patients) can be mitigated as soon as possible, i.e. well ahead of any potential disruption to supply. Thank you in advance for considering this request.

Please forward this notification to any colleagues to whom it would be of interest.

Should wish to discuss further or require additional information, please don't hesitate to contact Echo Therapeutics on 1300 848 328 or connect@echotherapeutics.net.

Kind Regards,



Jude D'Silva

Managing Director
Echo Therapeutics